CN106458915A - 新的伊伐布雷定盐及其制备方法 - Google Patents
新的伊伐布雷定盐及其制备方法 Download PDFInfo
- Publication number
- CN106458915A CN106458915A CN201580023762.6A CN201580023762A CN106458915A CN 106458915 A CN106458915 A CN 106458915A CN 201580023762 A CN201580023762 A CN 201580023762A CN 106458915 A CN106458915 A CN 106458915A
- Authority
- CN
- China
- Prior art keywords
- ivabradine
- embonate
- pharmaceutical composition
- pamoic acid
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 8
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical class C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 title abstract 2
- 229960003825 ivabradine Drugs 0.000 claims abstract description 21
- HLUKNZUABFFNQS-ZMBIFBSDSA-N ivabradine hydrochloride Chemical compound Cl.C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 HLUKNZUABFFNQS-ZMBIFBSDSA-N 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 229950005627 embonate Drugs 0.000 claims description 12
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 229960000504 ivabradine hydrochloride Drugs 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 230000033764 rhythmic process Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000035126 Facies Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- -1 Ivabradine hydrochlorides Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ZGBSOTLWHZQNLH-UHFFFAOYSA-N [Mg].S(O)(O)(=O)=O Chemical compound [Mg].S(O)(O)(=O)=O ZGBSOTLWHZQNLH-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
Abstract
本发明涉及式(I)的伊伐布雷定半双羟萘酸盐及其水合物。本发明还涉及药物。
Description
本发明涉及伊伐布雷定的新盐、其制备方法以及包含其的药物组合物。
伊伐布雷定或3-{3-[{[(7S)-3,4-二甲氧基二环[4.2.0]辛-1,3,5-三烯-7-基]甲基}(甲基)氨基]丙基}-7,8-二甲氧基-1,3,4,5-四氢-2H-3-苯并氮杂-2-酮，以及其可药用酸加成盐，更特别是其盐酸盐，具有非常有价值的药理学和治疗特性，尤其是减缓心率的特性，这使得这些化合物可用于治疗或预防心肌缺血的多种临床表现，例如心绞痛、心肌梗塞和相关的节律紊乱，以及涉及节律紊乱的多种疾病，尤其是室上性心律失常，并可用于收缩性心力衰竭和舒张性心力衰竭。
伊伐布雷定及其可药用酸加成盐、更特别是其盐酸盐的制备和治疗用途已经在欧洲专利EP 0 534 859中描述。
本发明涉及式(I)的伊伐布雷定的半双羟萘酸盐：
及其水合物，涉及制备所述盐的方法，以及包含其的药物组合物，特别是那些允许该活性成分随时间控制释放的组合物。
双羟萘酸也称为4,4'-甲烷二基二(3-羟基萘-2-甲酸)。
式(I)的化合物的伊伐布雷定/双羟萘酸比例为1/0.5。
式(I)的化合物通过将伊伐布雷定盐酸盐用双羟萘酸的二钠盐或双羟萘酸钠在水性介质中处理而获得。
将伊伐布雷定盐酸盐和双羟萘酸钠以1/0.5到1/0.6的比例混合。
接着，将由此制备的式(I)的化合物用有机溶剂如二氯甲烷从水性介质中萃取。
在式(I)的化合物形成后，可将其有利地溶于甲醇中，以除去残余的有机溶剂。
本发明还涉及药物组合物，其包含作为活性成分的伊伐布雷定半双羟萘酸盐以及一种或多种惰性的无毒的可药用赋形剂或载体。
对于本发明的药物组合物，可被特别提及的是那些适合于口服、胃肠外(静脉内、肌内或皮下)、经皮或透皮、鼻内、直肠、经舌、眼部或呼吸道给药的组合物，尤其是片剂、糖锭剂、舌下片剂、明胶胶囊、胶囊剂、栓剂、乳膏剂、软膏剂、表皮凝胶、可注射或可饮用的制剂、气雾剂、滴眼剂或滴鼻剂。
除了伊伐布雷定的半双羟萘酸盐，本发明的药物组合物还包含一种或多种赋形剂或载体，例如稀释剂、润滑剂、粘合剂、崩解剂、吸附剂、着色剂、甜味剂。
可被提及的赋形剂或载体的例子包括：
◆对于稀释剂：乳糖、葡萄糖、蔗糖、甘露醇、山梨醇、纤维素、甘油；
◆对于润滑剂：二氧化硅、滑石粉、硬脂酸及其镁盐和钙盐、聚乙二醇；
◆对于粘合剂：硅酸铝和硅酸镁、淀粉、麦芽糖糊精、明胶、黄蓍胶、甲基纤维素、羧甲基纤维素钠和聚乙烯吡咯烷酮；
◆对于崩解剂：琼脂、海藻酸及其钠盐、泡腾合剂。
在药物组合物中的伊伐布雷定半双羟萘酸盐的百分比优选为5％-50％重量。
所用剂量根据患者的性别、年龄和体重、给药途径、疾病性质和任何联合治疗的性质而变化，范围为每24小时2.5-30mg伊伐布雷定，更优选每天5-15mg，还更优选每天10-15mg。
药物组合物中稀释剂的百分比优选为40％-80％重量。
药物组合物中润滑剂的百分比优选为0.2％-10％重量。
药物组合物中粘合剂的百分比优选为5％-50％重量。
申请人已经发现，使用伊伐布雷定的半双羟萘酸盐能够制备具有活性成分控制释放的药物组合物，同时克服了常规方法产生的问题。
已经推荐和制备了多种用于药物活性成分的控制释放的药物组合物，用于其经口服、含服、舌下、眼部、直肠、阴道内和/或胃肠外途径给药。这些新的药物组合物的目标基本上是为了：
-减少药物的给药频率，
-在介质中或在预期的生物学位点获得相对恒定的活性成分水平，
-获得与药物的药理学活性相关的释放曲线。
最普遍用于控制释放的原理是将活性成分与赋形剂在基质中掺合，所述赋形剂大多数具有聚合物性质。
不论所面对的基质组成怎样，要获得它都会遇到具体的生产问题，例如：
-有很多步骤的复杂生产方法，
-活性成分在生产过程中的稳定性以及所用赋形剂的稳定性，
-调节活性成分释放速度很困难，通常随时间而变化，并且依赖于例如使用压制方法的聚合物批次的粒径，
-导致获得基本上仅适合一种给药途径的药物形式的生产方法，
-由于步骤的多次重复导致的批次间的重现性。
使用伊伐布雷定的半双羟萘酸盐能够获得活性成分的控制释放特性，不需要使用现有技术所描述的复杂的盖伦制剂技术。
因此，申请人已经显示，在本发明的药物组合物中使用伊伐布雷定的半双羟萘酸盐能够允许伊伐布雷定的控制释放，甚至当所用的盖伦制剂对应于使用伊伐布雷定盐酸盐来实现活性成分的立即释放的制剂时也是如此。
尽管全部的伊伐布雷定盐酸盐在体外在15分钟内释放，但本申请所述的体外溶出实验显示，在约6小时后仅有80％的伊伐布雷定半双羟萘酸盐被释放。
以下实施例举例说明本发明。
实施例1：制备伊伐布雷定的半双羟萘酸盐
元素分析在Carlo Erba 1108装置上进行。
结果用产品的水分含量校正，所述水分含量为1.82％(用库仑法测定)。
将4.1g的伊伐布雷定盐酸盐(8.12mmol)溶于200mL水中，将2.0g的双羟萘酸钠(4.63mmol)溶于200mL水中。
在剧烈搅拌下，将双羟萘酸钠溶液加入伊伐布雷定盐酸盐溶液中。立即沉淀形成半双羟萘酸盐。维持搅拌约30分钟，然后用200mL二氯甲烷第一次萃取伊伐布雷定的半双羟萘酸盐，接着用100mL二氯甲烷萃取第二次。合并有机部分，用100mL水清洗。有机相用硫酸镁干燥，得到澄清的黄色溶液。
将有机相在旋转蒸发仪中于40℃真空蒸发至干。得到黄色粉末。
将黄色粉末在40℃在真空中(10毫巴)干燥16小时，接着溶于200mL甲醇。
将溶液在旋转蒸发仪中于40℃真空蒸发至干。再次得到黄色粉末。
将黄色粉末在40℃在真空中(10毫巴)干燥20小时。
1H NMR谱显示残留甲醇含量为0.8％。
随后将粉末在80℃在真空中(10毫巴)再干燥24小时，得到3.53g产品，其具有的残留甲醇含量小于0.1％。
产率＝66.5％
元素分析：
| 元素 | ％理论值 | ％校正的平均值 |
| C | 69.77 | 69.40 |
| H | 6.69 | 6.60 |
| N | 4.23 | 4.25 |
| O | 19.31 |
校正结果的方法：
对于C的例子：69.14*100/(100-1.82)＝69.40％
对于H的例子：6.68*100/(100-1.82)–2*1.82/18＝6.60％(因为水的氢原子必须被考虑在内(2/18))
实施例2：药物组合物
包含剂量为5mg伊伐布雷定的100mg片剂的制剂配方
实施例3：溶出实验
溶出的操作条件
欧洲药典(2.9.3)描述的桨式溶出装置
溶出介质：0.01N盐酸(pH～2.1)，已脱气
介质温度：37℃±0.5℃
介质体积：500mL±5mL
桨叶旋转速度：50rpm±2rpm
标准取样时间：0、15、30和45min。
增加的取样时间：1、2、4、6、8、12和16h
移出体积：1mL
移出体积的替代：无
测试的单位数目：6
每瓶的单位数目：1
表1–溶出度结果
图1是上表所示数据的图解说明。
Claims (4)
1.式(I)的伊伐布雷定的半双羟萘酸盐：
以及其水合物。
2.制备伊伐布雷定半双羟萘酸盐的方法，其特征在于：在水性介质中将伊伐布雷定盐酸盐和双羟萘酸钠混合，伊伐布雷定盐酸盐和双羟萘酸钠的比例为1/0.5到1/0.6。
3.药物组合物，其包含作为活性成分的伊伐布雷定半双羟萘酸盐以及一种或多种惰性的无毒的可药用赋形剂或载体。
4.根据权利要求3的药物组合物，其用于治疗或预防心肌缺血的多种临床表现，例如心绞痛、心肌梗塞和相关的节律紊乱，以及涉及节律紊乱的多种疾病，尤其是室上性心律失常，以及收缩性心力衰竭或舒张性心力衰竭。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1454081 | 2014-05-06 | ||
| FR1454081A FR3020810B1 (fr) | 2014-05-06 | 2014-05-06 | Nouveau sel de l'ivabradine et son procede de preparation. |
| PCT/FR2015/051201 WO2015170053A1 (fr) | 2014-05-06 | 2015-05-06 | Nouveau sel de l'ivabradine et son procédé de préparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106458915A true CN106458915A (zh) | 2017-02-22 |
| CN106458915B CN106458915B (zh) | 2019-05-07 |
Family
ID=51518916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580023762.6A Active CN106458915B (zh) | 2014-05-06 | 2015-05-06 | 新的伊伐布雷定盐及其制备方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9856221B2 (zh) |
| EP (1) | EP3140287B1 (zh) |
| JP (1) | JP2017514848A (zh) |
| CN (1) | CN106458915B (zh) |
| AU (1) | AU2015257518B2 (zh) |
| CA (1) | CA2947475C (zh) |
| CY (1) | CY1120402T1 (zh) |
| DK (1) | DK3140287T3 (zh) |
| ES (1) | ES2672927T3 (zh) |
| FR (1) | FR3020810B1 (zh) |
| HR (1) | HRP20180716T1 (zh) |
| HU (1) | HUE037755T2 (zh) |
| LT (1) | LT3140287T (zh) |
| MA (1) | MA39756B1 (zh) |
| ME (1) | ME03062B (zh) |
| NO (1) | NO3140287T3 (zh) |
| PL (1) | PL3140287T3 (zh) |
| PT (1) | PT3140287T (zh) |
| RS (1) | RS57147B1 (zh) |
| SI (1) | SI3140287T1 (zh) |
| WO (1) | WO2015170053A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202402300A (zh) * | 2017-01-31 | 2024-01-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0534859B1 (fr) * | 1991-09-27 | 1994-11-17 | Adir Et Compagnie | 3-Benzazépin-zones substituées par un groupe benzocyclobutyl- ou indanyl-alkyl-amino-alkyle, utiles dans le traitement des affections cardiovasculaires |
| CN101386594A (zh) * | 2007-09-11 | 2009-03-18 | 瑟维尔实验室 | 1,2,4,5-四氢-3h-苯并氮杂䓬化合物、其制备方法与包含它们的药物组合物 |
| WO2011104723A2 (en) * | 2010-02-23 | 2011-09-01 | Ind-Swift Laboratories Limited | Acid addition salts of ivabradine and preparation thereof |
| WO2011157720A2 (en) * | 2010-06-14 | 2011-12-22 | Ratiopharm Gmbh | Ivabradine-containing pharmaceutical composition with modified release |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI832053L (fi) * | 1982-06-10 | 1983-12-11 | Syntex Inc | Nonapeptid- och dekapeptidanaloger av lhrh anvaendbara som lhrh-antagonister samt deras framstaellningsfoerfarande |
| DK1901749T3 (en) * | 2005-05-18 | 2016-10-24 | Raptor Pharmaceuticals Inc | Aerosolized fluoroquinolones AND USES THEREOF |
| WO2007064845A1 (en) * | 2005-11-29 | 2007-06-07 | Pr Pharmaceuticals, Inc. | Sustained release butorphanol drug delivery compositions for analgesia |
| US20080293695A1 (en) * | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
| US8653106B2 (en) * | 2010-07-30 | 2014-02-18 | Pisgah Laboratories, Inc. | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder |
| AU2010264670A1 (en) * | 2009-06-24 | 2012-01-19 | Merck Sharp & Dohme B.V. | Injectable formulations containing asenapine and method of treatment using same |
| FR2961105B1 (fr) * | 2010-06-15 | 2013-02-08 | Servier Lab | Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque |
| PL2702060T3 (pl) * | 2011-04-26 | 2016-06-30 | Torrent Pharmaceuticals Ltd | Kwasowe addycyjne sole risperidonu i ich kompozycje farmaceutyczne |
| CN102908327B (zh) * | 2011-08-05 | 2015-03-11 | 江苏恒瑞医药股份有限公司 | 伊伐布雷定或其可药用盐的缓释制剂 |
| US9079974B2 (en) * | 2011-12-21 | 2015-07-14 | The University Of Miami | GH-RH analogs with potent agonistic effects |
-
2014
- 2014-05-06 FR FR1454081A patent/FR3020810B1/fr not_active Expired - Fee Related
-
2015
- 2015-05-06 DK DK15725827.8T patent/DK3140287T3/en active
- 2015-05-06 MA MA39756A patent/MA39756B1/fr unknown
- 2015-05-06 ES ES15725827.8T patent/ES2672927T3/es active Active
- 2015-05-06 SI SI201530220T patent/SI3140287T1/en unknown
- 2015-05-06 RS RS20180447A patent/RS57147B1/sr unknown
- 2015-05-06 CA CA2947475A patent/CA2947475C/fr active Active
- 2015-05-06 PT PT157258278T patent/PT3140287T/pt unknown
- 2015-05-06 CN CN201580023762.6A patent/CN106458915B/zh active Active
- 2015-05-06 NO NO15725827A patent/NO3140287T3/no unknown
- 2015-05-06 LT LTEP15725827.8T patent/LT3140287T/lt unknown
- 2015-05-06 JP JP2016566206A patent/JP2017514848A/ja active Pending
- 2015-05-06 EP EP15725827.8A patent/EP3140287B1/fr active Active
- 2015-05-06 HU HUE15725827A patent/HUE037755T2/hu unknown
- 2015-05-06 ME MEP-2018-103A patent/ME03062B/me unknown
- 2015-05-06 AU AU2015257518A patent/AU2015257518B2/en active Active
- 2015-05-06 US US15/308,439 patent/US9856221B2/en active Active
- 2015-05-06 WO PCT/FR2015/051201 patent/WO2015170053A1/fr active Application Filing
- 2015-05-06 PL PL15725827T patent/PL3140287T3/pl unknown
-
2018
- 2018-05-02 CY CY20181100452T patent/CY1120402T1/el unknown
- 2018-05-09 HR HRP20180716TT patent/HRP20180716T1/hr unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0534859B1 (fr) * | 1991-09-27 | 1994-11-17 | Adir Et Compagnie | 3-Benzazépin-zones substituées par un groupe benzocyclobutyl- ou indanyl-alkyl-amino-alkyle, utiles dans le traitement des affections cardiovasculaires |
| CN101386594A (zh) * | 2007-09-11 | 2009-03-18 | 瑟维尔实验室 | 1,2,4,5-四氢-3h-苯并氮杂䓬化合物、其制备方法与包含它们的药物组合物 |
| WO2011104723A2 (en) * | 2010-02-23 | 2011-09-01 | Ind-Swift Laboratories Limited | Acid addition salts of ivabradine and preparation thereof |
| WO2011157720A2 (en) * | 2010-06-14 | 2011-12-22 | Ratiopharm Gmbh | Ivabradine-containing pharmaceutical composition with modified release |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3140287B1 (fr) | 2018-03-07 |
| US9856221B2 (en) | 2018-01-02 |
| WO2015170053A1 (fr) | 2015-11-12 |
| AU2015257518B2 (en) | 2018-12-13 |
| EP3140287A1 (fr) | 2017-03-15 |
| MA39756B1 (fr) | 2018-05-31 |
| RS57147B1 (sr) | 2018-07-31 |
| US20170050932A1 (en) | 2017-02-23 |
| JP2017514848A (ja) | 2017-06-08 |
| HRP20180716T1 (hr) | 2018-06-15 |
| CN106458915B (zh) | 2019-05-07 |
| SI3140287T1 (en) | 2018-05-31 |
| CA2947475C (fr) | 2018-07-10 |
| ES2672927T3 (es) | 2018-06-18 |
| PL3140287T3 (pl) | 2018-07-31 |
| NO3140287T3 (zh) | 2018-08-04 |
| AU2015257518A1 (en) | 2016-11-03 |
| CA2947475A1 (fr) | 2015-11-12 |
| LT3140287T (lt) | 2018-04-10 |
| DK3140287T3 (en) | 2018-06-14 |
| MA39756A (fr) | 2018-03-07 |
| PT3140287T (pt) | 2018-03-22 |
| ME03062B (me) | 2019-01-20 |
| FR3020810A1 (fr) | 2015-11-13 |
| FR3020810B1 (fr) | 2016-05-06 |
| HUE037755T2 (hu) | 2018-09-28 |
| CY1120402T1 (el) | 2019-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7625911B2 (en) | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion | |
| TWI699367B (zh) | 用於製備丁基原啡因之方法 | |
| JP5268902B2 (ja) | ピロロピリミジノン誘導体の塩およびその製造方法 | |
| EP3630726B1 (en) | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | |
| KR20200052349A (ko) | 엔독시펜을 제조 및 사용하는 방법 | |
| WO2009140887A1 (zh) | 一种灯盏花乙素衍生物及其制备方法、药物组合物和用途 | |
| CN107602546B (zh) | 化合物的晶型及其制备方法、组合物和应用 | |
| CN113201042A (zh) | 奥那司酮多晶型形式和使用方法 | |
| JP2006528948A (ja) | ピオグリタゾン塩、例えば硫酸ピオグリタゾン、およびそれを使用した医薬組成物および方法 | |
| CN106458915A (zh) | 新的伊伐布雷定盐及其制备方法 | |
| US20060100209A1 (en) | Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione | |
| JP2021523889A (ja) | Ｓ−アポモルフィンの結晶形 | |
| CN115124532B (zh) | 大黄酸与苦参碱共晶物及制备方法和其组合物与用途 | |
| CN115124420B (zh) | 大黄酸与苦参碱共晶物水合物及制备方法和其组合物与用途 | |
| CN103864756B (zh) | 丁二磺酸达比加群酯及其制备方法和用途 | |
| TW202104216A (zh) | Plk4抑制劑之結晶型 | |
| CN111909174B (zh) | 吡啶酮衍生物的晶型及制备方法和应用 | |
| CN106478764A (zh) | 丹参酮iia磷酸衍生物、及其合成和作为药物的应用 | |
| CN113831336A (zh) | 吡喹酮与阿魏酸共晶物及制备方法和其组合物与用途 | |
| CN103301067B (zh) | 一种改善吸收性能的固体分散体及其制备 | |
| KR20060026639A (ko) | 파록세틴의 콜린산 또는 콜린산 유도체 염, 및 파록세틴과콜린산 또는 콜린산 유도체의 조성물 | |
| CN114478542B (zh) | 一种化合物晶型及其制备方法和应用 | |
| CN106478765B (zh) | 丹参酮iia磺酸衍生物、及其合成和作为药物的应用 | |
| CN113260612B (zh) | 用于治疗或预防肌营养不良症的化合物及其在医药用途中的治疗、改善或预防用衍生物 | |
| CN110498761B (zh) | 乙酰金刚烷胺哌嗪(啶)类化合物作为脑神经保护剂应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1231876 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1231876 Country of ref document: HK |